Home Latest Articles
Latest Articles
  • Yunhong HUANG, Xiao LIU, Shuang LU, Chenyan GAO
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1654-1658.

    In recent years, with the progress of tumor immunotherapy and gene modification technology, chimeric antigen receptor T cells(CAR-T) has become a hot topic in drug research and development. CAR-T drugs targeting CD19 have significant therapeutic effects on acute lymphoblastic leukemia(ALL) in children, especially relapsed/refractory ALL with poor efficacy of conventional methods such as chemotherapy and hematopoietic stem cell transplantation. Several CAR-T products have been approved by drug regulatory administration for marketing, but no CAR-T products for children with ALL have been approved in China. This study mainly introduces the current situation of CAR-T products licensed to carry out drug clinical trials in China. Then the clinical needs and the critical elements of drug clinical research and development for acute B-cell lymphocytic leukemia in children is discussed, to provide reference for the design of registered clinical trials of similar products.

  • Duanduan CONG, Yanzhe SUN, Ying GENG, Zhimin YANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1659-1663.

    Children differ from adults in their tolerance to aversive feelings due to their physical and psychological developmental characteristics. They are also at a relatively higher risk of not taking medications as prescribed when the medication tastes unpleasant. Therefore, sound design and evaluation of the oral sensory features have important clinical significance and value in developing pediatric medications. This article briefly discussed the general considerations for the design and evaluation of the oral sensory features of pediatric medications based on the "Technical Guidance for the Design and Evaluation of the Oral Sensory Features of Pediatric Drugs (Draft)", which was released in June 2022, to draw attention of all parties to the design and evaluation of pediatric medications, evoke discussions, promote relevant research progress, and provide a reference for developing more suitable medicines for children's needs.

  • Ling TANG, Jun LYU, Lin XIA, Ying GENG, Zhimin YANG
    Chinese Journal of Pharmaceuticals. 2022, 53(11): 1664-1670.

    Antineoplastics are one of the most active fields in new drug research and development, but there are still obvious deficiencies in the research field of pediatric antineoplastics in China. And pediatric cancer patients have an urgent need for medication. Compared with clinical trials in adults, clinical trials of pediatric population often face more challenges, exacerbating the development dilemma of pediatric drug research and development. In order to encourage the research and development of pediatric antineoplastics in China, policy support should be given to activate the research motivation of manufacturing enterprises. In the process of research and development, attention should be paid to the differences between pediatric tumors and adult tumors, the mechanism research should be strengthened, and the research and development should be determined based on the characteristics and treatment needs of pediatric cancer patients. Meanwhile, we should use adult clinical data to support the development of pediatric antineoplastics, and make full use of quantitative pharmacology and other scientific tools, so as to reduce unnecessary researches in children. We should properly grasp the opportunity to carry out studies in pediatric population, especially in children and adults with comorbidity tumors, and promote the research and development of pediatric antineoplastics as soon as possible. In addition, the special needs of children, such as rational dosage forms and long-term safety, should also be fully considered in the research and development process.

  • Mengya HAO, Peixi ZHU, Feng SU, Weike SU
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1377-1385.

    Natural products are physiologically active chemical components extracted from natural resources. The key issue to enhance the utilization efficiency of natural products is to explore rapid, efficient and environmentally friendly extraction technologies. Mechanochemical-assisted extraction technology has the advantages of high yield, short extraction time and environmental-friendly. Thus, it has broad application prospects in the field of natural product extraction. This paper mainly introduces the method procedure, process principle, application mode and future trend of mechanochemical-assisted extraction technology. Meanwhile, the limitations of current mechanochemistry in industrial extraction applications are also discussed. Furthermore, the countermeasures are put forward. It could provide new research ideas for promoting the improvement and industrial applications of mechanochemical-assisted extraction technology.

  • Wei CHEN, Mingjie FENG, Bo XU, Yi PAN, Hua CHEN, Lida TANG
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1386-1393.

    Continuous flow chemistry is a promising new pharmaceutical technology, which has the advantages of reducing production cycle, higher automation, more environmentally friendly, energy-saving and emission reduction, and it also has the ability to perform chemical reactions that are difficult or impossible to do in batch manufacturing. It is the trend of active pharmaceutical ingredient(API) technology innovation. However, it has been slowly popularized in the pharmaceutical industry for a long time. With publication of ICH guideline Q13 on continuous manufacturing of drug substances and drug products, the key points of process development and control strategies have been put forward, and the regulatory expectation will gradually become clear. The characteristics, application scenarios and quality considerations of continuous flow chemistry are reviewed in this paper based on ICH Q13. Through literature research, the research points and control strategies of continuous flow chemistry are discussed, so as to promote the application of continuous flow chemistry in domestic pharmaceutical enterprises, improve the manufacturing level of the industry, strive to achieve carbon peaking and carbon neutrality goals.

  • Meng CAO, Yuanyuan GE, Yanchen HU, Yamin WANG, Yi CAO
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1394-1401.

    With the release of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH) Q13 guideline and the approval of several oral solid dosage form drug products adopting continuous manufacturing techniques, the regulatory development in this area is receiving increasing attention. Material handling is an important part of a continuous manufacturing platform. In this paper, the material handling for continuous manufacturing of oral solid dosage forms is introduced through analyzing the technical characteristics of material input, continuous feeding and continuous mixing. Also, the concerns of supervision and inspection are studied from the aspects of process validation, robustness, facilities and equipment, process control, quality assurance and cleaning. For technical consideration, process equipment should handle materials continuously and stably, with risks controlled and losses reduced as much as possible, so it is necessary to have a deep understanding of material characteristics, scientifically design process equipment and carry out qualification and verification; while regulatory inspections may focus on continuous process-specific risks and their possible effects on product quality. Hopefully this paper could accelerate the application of continuous manufacturing in pharmaceutical industry together with the aid of cooperation of regulation agencies, industrial community as well as the whole society, making full use of process analysis technology, innovative testing methods and digital quality assurance to steadily manufacture qualified products, thus promote domestic pharmaceutical industry to a high level of modernization.

  • Mengqing ZAN, Jianzhao NIU, Mingdi XU, Qian LIU
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1402-1407.

    The concept of continuous manufacturing and process analysis technology is expounded, and the relevant guiding principles of continuous pharmaceutical manufacturing and the consideration of relevant control strategies are introduced. Then, the principles, characteristics and application examples of commonly used analytical tools, such as near-infrared spectroscopy, Raman spectroscopy, terahertz pulsed imaging, ultrasound technique and X-ray microscopy imaging technology, in the continuous pharmaceutical manufacturing process are summarized. Finally, the factors affecting the continuous manufacturing of pharmaceuticals and the difficulties in the application of process analysis technology are reviewed, and the development direction of continuous pharmaceutical manufacturing is prospected. It is hoped to provide a reference for the development of process analysis technology related to continuous manufacturing.

  • Lu HUANG, Jian SUN, Mingwei WANG, Fan GE
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1408-1418.

    Three small molecule JAK inhibitors, namely ruxolitinib phosphate, fedratinib hydrochloride, and pacritinib citrate, for the treatment of myelofibrosis have been marketed worldwide. Their research progress and the published patents on chemical compound, crystalline form, salt form, process, formulation, drug combination, new use, and product derivatives, as well as the compounds in pharmaceutical research are unscrambled and researched in this paper. It is hoped to provide patent information and reference for Chinese pharmaceutical companies conducting project establishment and development, new patent mining, patent protection, and patent layout.

  • Xiaojie ZHANG, Qingzhu MIAO, Jingyang JIA, Chaoyu DU, Feng HE
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1419-1423.

    Five related substances of sufentanil citrate, namely N-[4-(methoxymethyl)piperidin-4-yl]-N-phenylpropionamide(related substance A), cis-4-(methoxymethyl)-4-(N-phenylpropionamido)-1-[2-(thiophen-2-yl)-ethyl]piperidine 1-oxide(related substance B), trans-4-(methoxymethyl)-4-(N-phenylpropionamido)-1-[2-(thiophen-2-yl)ethyl]piperidine 1-oxide(related substance Ⅰ), [4-(phenylamino)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]methanol(related substance C), and N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylacetamide citrate(related substance D). Their structures were confirmed by NMR and ESI-MS. These compounds may be used as the references in the quality control of sufentanil citrate.

  • Jing ZHANG, Jieyu ZHANG, Zi HUI, Jianwei ZHU, Junsheng CHEN
    Chinese Journal of Pharmaceuticals. 2022, 53(10): 1424-1431.

    Split intein-mediated protein trans-splicing is a promising technique with excellent prospects in many protein engineering fields. The naturally occurring cysteine-less split intein, Aes123 PolB1, can perform trans-splicing without reducing agents, which is particularly suitable for splicing proteins containing disulfide bonds. In this study, Aes123 PolB1 was used to splice proteins with the junction sequence EPK/SCD derived from the IgG hinge region in trans. The results showed that Aes123 PolB1 could successfully splice proteins with the EPK/SCD sequence without reducing agents. The factors that might affect the splicing activity, such as the concentration of sodium chloride, pH value, and temperature, were also investigated, and the results showed that the splicing reaction of Aes123 PolB1 could perform well in the EPK/SCD sequence. In this study, trans-splicing was performed under non-reducing conditions in the IgG hinge region amino acid sequences, which provided a theoretical and experimental basis for the application of split intein to seamlessly splicing antibody drugs, especially bispecific antibodies, under non-reducing conditions.

News